Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.

Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ.

Mol Ther. 2004 Sep;10(3):525-32.

2.

Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.

Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF.

Cancer Gene Ther. 2007 Mar;14(3):241-50. Epub 2006 Nov 10.

PMID:
17096027
3.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF.

J Urol. 2013 Sep;190(3):850-6. doi: 10.1016/j.juro.2013.03.030. Epub 2013 Mar 15.

4.

Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation.

Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, Benedict WF.

Cancer Gene Ther. 2006 Feb;13(2):125-30.

PMID:
16082384
5.

Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer.

Nagabhushan TL, Maneval DC, Benedict WF, Wen SF, Ihnat PM, Engler H, Connor RJ.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):389-94. Epub 2007 Aug 9. Review.

PMID:
17692556
7.
8.

Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation.

Yang Z, Zhang XQ, Dinney CN, Benedict WF.

Cancer Gene Ther. 2011 Sep;18(9):609-16. doi: 10.1038/cgt.2011.26. Epub 2011 Jun 17.

9.
10.
11.

Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer.

Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, Dinney CP.

J Urol. 2007 May;177(5):1900-6.

PMID:
17437845
12.

Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN.

Cancer Gene Ther. 2014 Mar;21(3):91-4. doi: 10.1038/cgt.2014.1. Epub 2014 Feb 7.

13.

An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.

Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF.

Cancer Gene Ther. 2000 Dec;7(12):1575-80.

14.

Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice.

Sazawa A, Watanabe T, Tanaka M, Haga K, Fujita H, Harabayashi T, Shinohara N, Koyanagi T, Kuzumaki N.

J Urol. 2002 Sep;168(3):1182-7.

PMID:
12187264
15.

Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.

Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF.

Cancer Gene Ther. 2002 Aug;9(8):687-91.

16.
17.

Nonviral cytokine gene therapy on an orthotopic bladder cancer model.

Wu Q, Mahendran R, Esuvaranathan K.

Clin Cancer Res. 2003 Oct 1;9(12):4522-8.

18.

Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.

Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.

Cancer Res. 2008 Jun 15;68(12):4506-10. doi: 10.1158/0008-5472.CAN-08-0238.

19.

The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer.

Frangos DN, Killion JJ, Fan D, Fishbeck R, von Eschenbach AC, Fidler IJ.

J Urol. 1990 Jun;143(6):1252-6.

PMID:
2342197
20.

A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.

Xiao Z, Mak A, Koch K, Moore RB.

BJU Int. 2013 Jul;112(2):E201-10. doi: 10.1111/j.1464-410X.2012.11737.x. Epub 2013 Jan 29.

Supplemental Content

Support Center